225 related articles for article (PubMed ID: 22039866)
1. Molecular mechanisms and proposed targets for selected anticancer gold compounds.
Casini A; Messori L
Curr Top Med Chem; 2011; 11(21):2647-60. PubMed ID: 22039866
[TBL] [Abstract][Full Text] [Related]
2. Protein targets for anticancer gold compounds: mechanistic inferences.
Gabbiani C; Messori L
Anticancer Agents Med Chem; 2011 Dec; 11(10):929-39. PubMed ID: 21864237
[TBL] [Abstract][Full Text] [Related]
3. Proteasome versus Thioredoxin Reductase Competition as Possible Biological Targets in Antitumor Mixed Thiolate-Dithiocarbamate Gold(III) Complexes.
Quero J; Cabello S; Fuertes T; Mármol I; Laplaza R; Polo V; Gimeno MC; Rodriguez-Yoldi MJ; Cerrada E
Inorg Chem; 2018 Sep; 57(17):10832-10845. PubMed ID: 30117739
[TBL] [Abstract][Full Text] [Related]
4. Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes.
Ronconi L; Aldinucci D; Dou QP; Fregona D
Anticancer Agents Med Chem; 2010 May; 10(4):283-92. PubMed ID: 20184554
[TBL] [Abstract][Full Text] [Related]
5. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies.
Nobili S; Mini E; Landini I; Gabbiani C; Casini A; Messori L
Med Res Rev; 2010 May; 30(3):550-80. PubMed ID: 19634148
[TBL] [Abstract][Full Text] [Related]
6. Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway.
Saggioro D; Rigobello MP; Paloschi L; Folda A; Moggach SA; Parsons S; Ronconi L; Fregona D; Bindoli A
Chem Biol; 2007 Oct; 14(10):1128-39. PubMed ID: 17961825
[TBL] [Abstract][Full Text] [Related]
7. Phosphine-gold(I) compounds as anticancer agents: general description and mechanisms of action.
Lima JC; Rodriguez L
Anticancer Agents Med Chem; 2011 Dec; 11(10):921-8. PubMed ID: 21864238
[TBL] [Abstract][Full Text] [Related]
8. New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status.
Altaf M; Monim-Ul-Mehboob M; Kawde AN; Corona G; Larcher R; Ogasawara M; Casagrande N; Celegato M; Borghese C; Siddik ZH; Aldinucci D; Isab AA
Oncotarget; 2017 Jan; 8(1):490-505. PubMed ID: 27888799
[TBL] [Abstract][Full Text] [Related]
9. Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action.
Casini A; Hartinger C; Gabbiani C; Mini E; Dyson PJ; Keppler BK; Messori L
J Inorg Biochem; 2008 Mar; 102(3):564-75. PubMed ID: 18177942
[TBL] [Abstract][Full Text] [Related]
10. Stable anticancer gold(III)-porphyrin complexes: effects of porphyrin structure.
Sun RW; Li CK; Ma DL; Yan JJ; Lok CN; Leung CH; Zhu N; Che CM
Chemistry; 2010 Mar; 16(10):3097-113. PubMed ID: 20162647
[TBL] [Abstract][Full Text] [Related]
11. Strategies for the biological evaluation of gold anticancer agents.
Fricker SP
Anticancer Agents Med Chem; 2011 Dec; 11(10):940-52. PubMed ID: 21864236
[TBL] [Abstract][Full Text] [Related]
12. Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities.
Micale N; Schirmeister T; Ettari R; Cinellu MA; Maiore L; Serratrice M; Gabbiani C; Massai L; Messori L
J Inorg Biochem; 2014 Dec; 141():79-82. PubMed ID: 25217719
[TBL] [Abstract][Full Text] [Related]
13. A cancer-targeted nanosystem for delivery of gold(III) complexes: enhanced selectivity and apoptosis-inducing efficacy of a gold(III) porphyrin complex.
He L; Chen T; You Y; Hu H; Zheng W; Kwong WL; Zou T; Che CM
Angew Chem Int Ed Engl; 2014 Nov; 53(46):12532-6. PubMed ID: 25220408
[TBL] [Abstract][Full Text] [Related]
14. New comprehensive studies of a gold(III) Dithiocarbamate complex with proven anticancer properties: Aqueous dissolution with cyclodextrins, pharmacokinetics and upstream inhibition of the ubiquitin-proteasome pathway.
Tomasello MF; Nardon C; Lanza V; Di Natale G; Pettenuzzo N; Salmaso S; Milardi D; Caliceti P; Pappalardo G; Fregona D
Eur J Med Chem; 2017 Sep; 138():115-127. PubMed ID: 28651154
[TBL] [Abstract][Full Text] [Related]
15. Insights into the reactivity of gold-dithiocarbamato anticancer agents toward model biomolecules by using multinuclear NMR spectroscopy.
Boscutti G; Marchiò L; Ronconi L; Fregona D
Chemistry; 2013 Sep; 19(40):13428-36. PubMed ID: 24038383
[TBL] [Abstract][Full Text] [Related]
16. Density functional theory study of gold(III)-dithiocarbamate complexes with characteristic anticancer potentials.
Lawal MM; Lawal IA; Klink MJ; Tolufashe GF; Ndagi U; Kumalo HM
J Inorg Biochem; 2020 May; 206():111044. PubMed ID: 32120162
[TBL] [Abstract][Full Text] [Related]
17. Gold(III) complexes in medicinal chemistry.
Maia PI; Deflon VM; Abram U
Future Med Chem; 2014 Sep; 6(13):1515-36. PubMed ID: 25365235
[TBL] [Abstract][Full Text] [Related]
18. Gold(i) and gold(iii) phosphine complexes: synthesis, anticancer activities towards 2D and 3D cancer models, and apoptosis inducing properties.
Srinivasa Reddy T; Privér SH; Rao VV; Mirzadeh N; Bhargava SK
Dalton Trans; 2018 Nov; 47(43):15312-15323. PubMed ID: 30187047
[TBL] [Abstract][Full Text] [Related]
19. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts.
Milacic V; Chen D; Ronconi L; Landis-Piwowar KR; Fregona D; Dou QP
Cancer Res; 2006 Nov; 66(21):10478-86. PubMed ID: 17079469
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability.
Gabbiani C; Casini A; Kelter G; Cocco F; Cinellu MA; Fiebig HH; Messori L
Metallomics; 2011 Dec; 3(12):1318-23. PubMed ID: 21887452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
